11/18
04:05 pm
ctxr
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering
High
Report
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering
11/15
01:30 pm
ctxr
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering
High
Report
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering
11/12
08:33 am
ctxr
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Low
Report
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
11/11
08:45 am
ctxr
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors
Low
Report
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors
9/5
04:30 pm
ctxr
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Low
Report
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
9/5
08:30 am
ctxr
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
Medium
Report
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology